Brief: Paion Says Receives European Commission Approval Of Byfavo (Remimazolam) For Procedural Sedation
27/03/2021 12:50
March 27 (Reuters) - Paion AG PA8G.DE :
* RECEIVES EUROPEAN COMMISSION APPROVAL OF BYFAVO(R)
(REMIMAZOLAM)
FOR PROCEDURAL SEDATION
* EUROPEAN COMMISSION (EC) HAS APPROVED BYFAVO(REMIMAZOLAM)
IN
ADULTS FOR PROCEDURAL SEDATION
Source text for Eikon: ID:nEQcd6w7Xa
Further company coverage: PA8G.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022